Aberdeen Group plc Increases Stake in Vaxcyte, Inc. $PCVX

Aberdeen Group plc lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 70.1% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 722,793 shares of the company’s stock after purchasing an additional 297,886 shares during the period. Aberdeen Group plc’s holdings in Vaxcyte were worth $26,035,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. State Street Corp boosted its holdings in shares of Vaxcyte by 12.1% during the 2nd quarter. State Street Corp now owns 4,942,235 shares of the company’s stock worth $160,672,000 after purchasing an additional 534,552 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in Vaxcyte by 42.4% during the second quarter. Westfield Capital Management Co. LP now owns 3,068,898 shares of the company’s stock worth $99,770,000 after buying an additional 913,761 shares in the last quarter. Geode Capital Management LLC lifted its position in Vaxcyte by 5.0% during the second quarter. Geode Capital Management LLC now owns 3,011,140 shares of the company’s stock worth $97,903,000 after buying an additional 142,086 shares in the last quarter. Jennison Associates LLC boosted its stake in Vaxcyte by 24.3% during the second quarter. Jennison Associates LLC now owns 1,399,299 shares of the company’s stock worth $45,491,000 after buying an additional 273,579 shares during the last quarter. Finally, Maverick Capital Ltd. grew its holdings in Vaxcyte by 8.5% in the 2nd quarter. Maverick Capital Ltd. now owns 1,310,605 shares of the company’s stock valued at $42,608,000 after buying an additional 102,512 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other news, insider Harpreet S. Dhaliwal sold 9,743 shares of the company’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the completion of the transaction, the insider directly owned 23,928 shares of the company’s stock, valued at approximately $1,117,198.32. This represents a 28.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Elvia Cowan sold 11,623 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the transaction, the senior vice president directly owned 14,534 shares of the company’s stock, valued at $696,469.28. This trade represents a 44.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.10% of the stock is currently owned by insiders.

Vaxcyte Trading Down 1.4%

Vaxcyte stock opened at $53.33 on Wednesday. The firm has a market capitalization of $6.98 billion, a P/E ratio of -11.02 and a beta of 1.33. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $85.22. The stock’s fifty day simple moving average is $49.26 and its 200-day simple moving average is $42.51.

Analyst Ratings Changes

Several brokerages have recently weighed in on PCVX. Guggenheim reissued a “buy” rating and set a $116.00 price target on shares of Vaxcyte in a research report on Monday, February 2nd. Needham & Company LLC boosted their target price on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Leerink Partners set a $77.00 price target on shares of Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of Vaxcyte in a report on Monday, November 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $93.83.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.